EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate

Sophia Stanford iD, Ashok Roy iD, Tom Cecil, Oliver Hegener, Petra Schulz, Anna Turaj, Sean Lim, Emily Arbuthnot

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0290571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Sophia Stanford und 7 weiteren Autor:innen. Beteiligte Einrichtung: Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom. Hauptthemen laut MEDLINE: Cell-Derived Microparticles, Hematologic Agents, Hemostatics. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Octapharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Variable fibrinogen content within cryoprecipitate makes accurate dosing challenging in patients with coagulopathic bleeding, in addition to pathogen transmission risks associated with its administration. Purified and standardized human fibrinogen concentrates (HFCs) represent reliable alternatives. Full cryoprecipitate characterization is required to inform selection of an appropriate fibrinogen source for supplementation therapy.

Methods

Extended biochemical comparison of pooled cryoprecipitate and HFC ( Fibryga , Octapharma) was performed using commercially available assays to determine levels of variability in cryoprecipitate and HFC. In addition to standard procoagulant factors, measurements included activities of platelet-derived microparticles (PMPs) and plasminogen, and levels of fibrin degradation products.

Results

Cryoprecipitate contains lower fibrinogen levels than HFC (4.83 vs .19.73 g/L; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Derived MicroparticlesHematologic AgentsHemostaticsHumansFibrinogenvon Willebrand FactorBlood CoagulationSerine Proteases

Substanzen

Fibrinogenvon Willebrand FactorHematologic AgentsHemostaticsSerine Proteases

Autor:innen und Institutionen

  • Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom.
  • Octapharma AG, Lachen, Switzerland.
  • Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria.
  • Faculty of Medicine, Centre for Cancer Immunology, University of Southampton, University Hospital Southampton, Southampton, United Kingdom.

ORCID-Profile: Sophia Stanford, Ashok Roy

Förderung

  • Octapharma AG

Zitieren

APA

Stanford, S., Roy, A., Cecil, T., Hegener, O., Schulz, P., Turaj, A., Lim, S., & Arbuthnot, E. (2023). Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate. PLOS ONE. https://doi.org/10.1371/journal.pone.0290571

Vancouver

Stanford S, Roy A, Cecil T, Hegener O, Schulz P, Turaj A, et al. Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate. PLOS ONE. 2023. doi:10.1371/journal.pone.0290571

BibTeX
@article{Stanford2023,
  author = {Stanford, Sophia and Roy, Ashok and Cecil, Tom and Hegener, Oliver and Schulz, Petra and Turaj, Anna and Lim, Sean and Arbuthnot, Emily},
  title = {Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0290571}
}
Kostenlos starten →